Latest news and press releases about Lunai Bioworks Inc. (LNAI): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
Price
| Price | $2.17 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -0.71 |
| EV / EBITDA | -0.07 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 892.52% |
| Return on Invested Capital | 120.87% |
| Return on Assets | -1300.98% |
| Gross Margin | -360.71% |
| Operating Margin | -46991.97% |
| Net Margin | -612568.11% |
Related companies: ADAP · ANL · APLM · BLRX · ERNA · GOVX · ICU
Explore sector: Healthcare · Biotechnology
More sections of LNAI: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks